Condition: Carcinoma · Upper Tract Urothelial Carcinoma · UTUC · Sponsor: Jinling Hospital, China
This study will evaluate the efficacy and safety of intravenous RC48-ADC combined with JS001 in postoperative adjuvant therapy for HER2-positive upper tract urothelial carcinoma.
This description comes directly from the study's public registry record.
Le Qu, M.D. · 15720625951 · septsoul@hotmail.com
Always discuss trial participation with your own doctor first.
| Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05917158